Categories AlphaGraphs, Earnings, Health Care

ABBV Earnings: Highlights of AbbVie’s Q2 2022 financial results

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) has reported double-digit growth in second-quarter adjusted earnings, reflecting an increase in revenues. The company also provided earnings guidance for fiscal 2022.

Abbvie Q2 2022 earnings infographics

Total revenues increased 5% year-over-year to $14.6 billion, aided by a strong performance by the immunology and neuroscience segments.

At $3.37 per share, adjusted net income was up 11% year-over-year. Unadjusted profit increased sharply to $924 million or $0.51 per share from $766 million or $0.42 per share in the second quarter of 2021.


Check this space to read management/analysts’ comments on AbbVie’s Q2 2022 earnings


“We delivered another strong quarter with substantial progress for our new products and indications. Importantly, Skyrizi and Rinvoq continued their impressive ramps and are on pace to deliver approximately $7.5 billion in combined annual sales, underscoring their significant potential,” said Richard A. Gonzalez, CEO of AbbVie.

Most Popular

AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates

Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the

Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights

Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose

Meta Platforms (META) set to report Q1 earnings. Here’s what to expect

After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top